Document Detail


Low-dose non-enhanced CT versus full-dose contrast-enhanced CT in integrated PET/CT studies for the diagnosis of uterine cancer recurrence.
MedLine Citation:
PMID:  20386901     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: To evaluate low-dose non-enhanced CT (ldCT) and full-dose contrast-enhanced CT (ceCT) in integrated (18)F-fluorodeoxyglucose (FDG) PET/CT studies for restaging of uterine cancer.
METHODS: A group of 100 women who had undergone treatment for uterine cervical (n=55) or endometrial cancer (n=45) underwent a conventional PET/CT scans with ldCT, and then a ceCT scan. Two observers retrospectively reviewed and interpreted the PET/ldCT and PET/ceCT images in consensus using a three-point grading scale (negative, equivocal, or positive) per patient and per lesion. Final diagnoses were obtained by histopathological examination, or clinical follow-up for at least 6 months.
RESULTS: Patient-based analysis showed that the sensitivity, specificity and accuracy of PET/ceCT were 90% (27/30), 97% (68/70) and 95% (95/100), respectively, whereas those of PET/ldCT were 83% (25/30), 94% (66/70) and 91% (91/100), respectively. Sensitivity, specificity and accuracy did not significantly differ between two methods (McNemar test, p=0.48, p=0.48, and p=0.13, respectively). There were 52 sites of lesion recurrence: 12 pelvic lymph node (LN), 11 local recurrence, 8 peritoneum, 7 abdominal LN, 5 lung, 3 supraclavicular LN, 3 liver, 2 mediastinal LN, and 1 muscle and bone. The grading results for the 52 sites of recurrence were: negative 5, equivocal 0 and positive 47 for PET/ceCT, and negative 5, equivocal 4 and positive 43 for PET/ldCT, respectively. Four equivocal regions by PET/ldCT (local recurrence, pelvic LN metastasis, liver metastasis and muscle metastasis) were correctly interpreted as positive by PET/ceCT.
CONCLUSION: PET/ceCT is an accurate imaging modality for the assessment of uterine cancer recurrence. Its use reduces the frequency of equivocal interpretations.
Authors:
Kazuhiro Kitajima; Kayo Suzuki; Yuji Nakamoto; Yumiko Onishi; Setsu Sakamoto; Michio Senda; Masato Kita; Kazuro Sugimura
Publication Detail:
Type:  Journal Article     Date:  2010-04-13
Journal Detail:
Title:  European journal of nuclear medicine and molecular imaging     Volume:  37     ISSN:  1619-7089     ISO Abbreviation:  Eur. J. Nucl. Med. Mol. Imaging     Publication Date:  2010 Aug 
Date Detail:
Created Date:  2010-08-04     Completed Date:  2011-01-04     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101140988     Medline TA:  Eur J Nucl Med Mol Imaging     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  1490-8     Citation Subset:  IM    
Affiliation:
Department of PET Diagnosis, Institute of Biomedical Research and Innovation, 2-2 Minatojima-Nakamachi, Chuo-ku, Kobe 650-0047, Japan. kitajima@med.kobe-u.ac.jp
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aged, 80 and over
Contrast Media / diagnostic use*
Female
Humans
Middle Aged
Positron-Emission Tomography / methods*
Radiation Dosage*
Recurrence
Retrospective Studies
Tomography, X-Ray Computed / methods*
Uterine Neoplasms / radiography*,  radionuclide imaging*
Chemical
Reg. No./Substance:
0/Contrast Media

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Adsorption of proteins on a lipid bilayer.
Next Document:  Secondary and tertiary hyperparathyroidism: the utility of ioPTH monitoring.